A detailed history of Graham Capital Management, L.P. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Graham Capital Management, L.P. holds 4,358 shares of CRSP stock, worth $201,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,358
Previous 5,309 17.91%
Holding current value
$201,731
Previous $286,000 28.67%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$44.62 - $62.75 $42,433 - $59,675
-951 Reduced 17.91%
4,358 $204,000
Q2 2024

Aug 14, 2024

BUY
$51.17 - $68.18 $271,661 - $361,967
5,309 New
5,309 $286,000
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $300,855 - $469,036
6,921 New
6,921 $388,000
Q2 2022

Aug 15, 2022

BUY
$43.23 - $73.83 $269,711 - $460,625
6,239 Added 140.9%
10,667 $648,000
Q1 2022

May 16, 2022

BUY
$53.19 - $79.24 $235,525 - $350,874
4,428 New
4,428 $277,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.